Terguride in stable Parkinson's disease

E. Martignoni, C. Pacchetti, B. Aufdembrinke, L. Godi, G. Albani, F. Mancini, G. Nappi

Research output: Contribution to journalArticle


Terguride (TER) (2 mg/day) was compared with a placebo in 41 stable Parkinson's disease (PD) patients, so as to test its efficacy as an add-on treatment to spare levodopa (LD). After the 4th week of add-on treatment, LD was reduced by about 25%. The number of 'stable' patients (- those with an increase of no more than 20% of the basal Columbia University Rating Scale (CURS) score - remaining after LD reduction was used to compare the two add-on treatments. Most patients, remained 'stable' in spite of LD reduction, and no significant differences between the therapies were discovered; the CURS score decreased over time only in the TER group. Hence, TER was shown to be a drug that has DA-ergic properties but with minimal antiparkinonian efficacy.

Original languageEnglish
Pages (from-to)143-146
Number of pages4
JournalFunctional Neurology
Issue number3
Publication statusPublished - 1995


  • Parkinson's disease
  • Sparing levodopa
  • Terguride

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Terguride in stable Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this

    Martignoni, E., Pacchetti, C., Aufdembrinke, B., Godi, L., Albani, G., Mancini, F., & Nappi, G. (1995). Terguride in stable Parkinson's disease. Functional Neurology, 10(3), 143-146.